Kevin Y. Urayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kevin Y. Urayama has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Naho Morisaki
Department of Social Medicine, National Center for Child Health and Development, Tokyo, Japan
5 shared publications - Atsushi Manabe
Department of Pediatrics Hokkaido University Graduate School of Medicine Sapporo Japan
3 shared publications - Masatoshi Takagi
Department of Pediatrics and Developmental Biology Institute of Science Tokyo Tokyo Japan
3 shared publications Aurelie Piedvache
Department of Social Medicine National Center for Child Health and Development Tokyo Japan
2 shared publications- Catherine Metayer
Division of Epidemiology, School of Public Health University of California Berkeley California USA
2 shared publications Dai Keino
Department of Hematology/Oncology, Children's Cancer Center Kanagawa Children's Medical Center Kanagawa Japan
2 shared publications
Latest Publications
- Open Access
- 23 May 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (4) , 1807-1827
Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan
Migraine is a chronic, disabling neurological disorder affecting the Japanese population, with a significant impact on quality of life and daily activities. Lasmiditan, a selective 5-HT1F receptor agonist approved for acute migraine treatment, provides an alternative for patients who cannot tolerate or do not respond to existing therapies, including triptans. The study aimed to evaluate the real-world safety and effectiveness of lasmiditan in Japanese patients with migraine as part of post-marketing pharmacovigilance requirements. This single-arm, multicenter, non-interventional, prospective observational study enrolled 550 patients from 53 medical sites across Japan. Patients newly prescribed lasmiditan for acute migraine between June 2022 and September 2024 were included. Data were collected via electronic case report forms, eDiaries, and questionnaires. Safety assessments included adverse events (AEs), serious AEs (SAEs), and treatment-emergent AEs (TEAEs). Effectiveness was evaluated by pain freedom and pain relief at 2 h post-dose. Data were summarized using descriptive statistics. Of the 400 patients analyzed for safety (mean age 40.5 years; 79.5% female), 56.0% received 50 mg and 42.8% received 100 mg lasmiditan as the initial dose. About 41.8% experienced at least one TEAE, with no SAEs or deaths. The most common TEAEs were dizziness (8.4%) and somnolence (3.9%) with a median time to resolution of 3 and 4 h, respectively. In the effectiveness analysis set (n = 328), for moderate-to-severe headache, 21.5% and 53.9% achieved pain freedom or pain relief, respectively, 2 h post-first dose. For specific daily activities, 45.9% of work or school tasks improved from "severely disturbed" and "couldn't move" to "no problem" or "slightly disturbed" after 2 h. Lasmiditan was associated with a manageable safety profile and effectiveness in patients with acute migraine in routine clinical practice in Japan, with no new safety concerns identified.
- 23 May 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (4) , 1807-1827
Open AccessReal-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan
Migraine is a chronic, disabling neurological disorder affecting the Japanese population, with a significant impact on quality of life and daily activities. Lasmiditan, a selective 5-HT1F receptor agonist approved for acute migraine treatment, provides an alternative for patients who cannot tolerate or do not respond to existing therapies, including triptans. The study aimed to evaluate the real-world safety and effectiveness of lasmiditan in Japanese patients with migraine as part of post-marketing pharmacovigilance requirements. This single-arm, multicenter, non-interventional, prospective observational study enrolled 550 patients from 53 medical sites across Japan. Patients newly prescribed lasmiditan for acute migraine between June 2022 and September 2024 were included. Data were collected via electronic case report forms, eDiaries, and questionnaires. Safety assessments included adverse events (AEs), serious AEs (SAEs), and treatment-emergent AEs (TEAEs). Effectiveness was evaluated by pain freedom and pain relief at 2 h post-dose. Data were summarized using descriptive statistics. Of the 400 patients analyzed for safety (mean age 40.5 years; 79.5% female), 56.0% received 50 mg and 42.8% received 100 mg lasmiditan as the initial dose. About 41.8% experienced at least one TEAE, with no SAEs or deaths. The most common TEAEs were dizziness (8.4%) and somnolence (3.9%) with a median time to resolution of 3 and 4 h, respectively. In the effectiveness analysis set (n = 328), for moderate-to-severe headache, 21.5% and 53.9% achieved pain freedom or pain relief, respectively, 2 h post-first dose. For specific daily activities, 45.9% of work or school tasks improved from "severely disturbed" and "couldn't move" to "no problem" or "slightly disturbed" after 2 h. Lasmiditan was associated with a manageable safety profile and effectiveness in patients with acute migraine in routine clinical practice in Japan, with no new safety concerns identified.
- Open Access
- 25 January 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (4) , 435-446
Safety and effectiveness of selpercatinib in patients with RET fusion-positive non-small cell lung cancer in real-world clinical practice: a postmarketing study in Japan
Background: This study assessed the safety and effectiveness of selpercatinib, a selective rearranged during transfection (RET) kinase inhibitor, in patients with RET fusion-positive non-small cell lung cancer (NSCLC) in real-world clinical practice in Japan. Methods: This single-arm, multicenter, prospective observational study included patients with RET fusion-positive NSCLC who received at least one dose of selpercatinib between February 2022 and October 2023. Data were extracted from medical records and entered into an electronic data capture (eDC) system. Safety (adverse events [AEs] and AEs of special interest [AESIs]) and effectiveness (tumor response, overall survival [OS]) were assessed over 12 months. Results: Among 243 patients (median age: 67 years; 56% females), AEs occurred in 86.0% of patients, with Grade ≥ 3 AEs in 48.1% and serious AEs (SAEs) in 24.7%. The most common AEs (≥10%) included hypertension (23.5%), abnormal hepatic function (21.0%), rash (11.1%), aspartate aminotransferase increase (10.3%), and diarrhea (10.3%). AEs led to treatment modifications, including dose interruption (54.7%), dose reduction (14.8%), and discontinuation (6.2%). AESIs included liver injury (44.0%), hypertension-related events (23.9%), and hypersensitivity (MedDRA preferred term; 9.9%). The overall response rate was 58.8%, comprising complete response in 4.5% and partial response in 54.3% of patients. Median OS was not reached; the 12-month survival rate was 80.9% (95% CI, 74.9–85.6). Conclusions: Real-world data showed selpercatinib to be effective in patients with RET fusion-positive NSCLC in Japan, with a favorable safety profile and no new safety concerns.
- 25 January 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (4) , 435-446
Open AccessSafety and effectiveness of selpercatinib in patients with RET fusion-positive non-small cell lung cancer in real-world clinical practice: a postmarketing study in Japan
Background: This study assessed the safety and effectiveness of selpercatinib, a selective rearranged during transfection (RET) kinase inhibitor, in patients with RET fusion-positive non-small cell lung cancer (NSCLC) in real-world clinical practice in Japan. Methods: This single-arm, multicenter, prospective observational study included patients with RET fusion-positive NSCLC who received at least one dose of selpercatinib between February 2022 and October 2023. Data were extracted from medical records and entered into an electronic data capture (eDC) system. Safety (adverse events [AEs] and AEs of special interest [AESIs]) and effectiveness (tumor response, overall survival [OS]) were assessed over 12 months. Results: Among 243 patients (median age: 67 years; 56% females), AEs occurred in 86.0% of patients, with Grade ≥ 3 AEs in 48.1% and serious AEs (SAEs) in 24.7%. The most common AEs (≥10%) included hypertension (23.5%), abnormal hepatic function (21.0%), rash (11.1%), aspartate aminotransferase increase (10.3%), and diarrhea (10.3%). AEs led to treatment modifications, including dose interruption (54.7%), dose reduction (14.8%), and discontinuation (6.2%). AESIs included liver injury (44.0%), hypertension-related events (23.9%), and hypersensitivity (MedDRA preferred term; 9.9%). The overall response rate was 58.8%, comprising complete response in 4.5% and partial response in 54.3% of patients. Median OS was not reached; the 12-month survival rate was 80.9% (95% CI, 74.9–85.6). Conclusions: Real-world data showed selpercatinib to be effective in patients with RET fusion-positive NSCLC in Japan, with a favorable safety profile and no new safety concerns.
- Open Access
- 21 June 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 33 (9) , 1248-1252
Folate Metabolism and Risk of Childhood Acute Lymphoblastic Leukemia: A Genetic Pathway Analysis from the Childhood Cancer and Leukemia International Consortium
Background: Prenatal folate supplementation has been consistently associated with a reduced risk of childhood acute lymphoblastic leukemia (ALL). Previous germline genetic studies examining the one carbon (folate) metabolism pathway were limited in sample size, scope, and population diversity and led to inconclusive results. Methods: We evaluated whether ∼2,900 single-nucleotide polymorphisms (SNP) within 46 candidate genes involved in the folate metabolism pathway influence the risk of childhood ALL, using genome-wide data from nine case-control studies in the Childhood Cancer and Leukemia International Consortium (n = 9,058 cases including 4,510 children of European ancestry, 3,018 Latinx, and 1,406 Asians, and 92,364 controls). Each study followed a standardized protocol for quality control and imputation of genome-wide data and summary statistics were meta-analyzed for all children combined and by major ancestry group using METAL software. Results: None of the selected SNPs reached statistical significance, overall and for major ancestry groups (using adjusted Bonferroni P-value of 5 × 10−6 and less-stringent P-value of 3.5 × 10−5 accounting for the number of “independent” SNPs). None of the 10 top (nonsignificant) SNPs and corresponding genes overlapped across ancestry groups. Conclusions: This large meta-analysis of original data does not reveal associations between many common genetic variants in the folate metabolism pathway and childhood ALL in various ancestry groups. Impact: Genetic variants in the folate pathway alone do not appear to substantially influence childhood acute lymphoblastic leukemia risk. Other mechanisms such as gene–folate interaction, DNA methylation, or maternal genetic effects may explain the observed associations with self-reported prenatal folate intake.
- 21 June 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 33 (9) , 1248-1252
Open AccessFolate Metabolism and Risk of Childhood Acute Lymphoblastic Leukemia: A Genetic Pathway Analysis from the Childhood Cancer and Leukemia International Consortium
Background: Prenatal folate supplementation has been consistently associated with a reduced risk of childhood acute lymphoblastic leukemia (ALL). Previous germline genetic studies examining the one carbon (folate) metabolism pathway were limited in sample size, scope, and population diversity and led to inconclusive results. Methods: We evaluated whether ∼2,900 single-nucleotide polymorphisms (SNP) within 46 candidate genes involved in the folate metabolism pathway influence the risk of childhood ALL, using genome-wide data from nine case-control studies in the Childhood Cancer and Leukemia International Consortium (n = 9,058 cases including 4,510 children of European ancestry, 3,018 Latinx, and 1,406 Asians, and 92,364 controls). Each study followed a standardized protocol for quality control and imputation of genome-wide data and summary statistics were meta-analyzed for all children combined and by major ancestry group using METAL software. Results: None of the selected SNPs reached statistical significance, overall and for major ancestry groups (using adjusted Bonferroni P-value of 5 × 10−6 and less-stringent P-value of 3.5 × 10−5 accounting for the number of “independent” SNPs). None of the 10 top (nonsignificant) SNPs and corresponding genes overlapped across ancestry groups. Conclusions: This large meta-analysis of original data does not reveal associations between many common genetic variants in the folate metabolism pathway and childhood ALL in various ancestry groups. Impact: Genetic variants in the folate pathway alone do not appear to substantially influence childhood acute lymphoblastic leukemia risk. Other mechanisms such as gene–folate interaction, DNA methylation, or maternal genetic effects may explain the observed associations with self-reported prenatal folate intake.
- 11 November 2023
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (3) , 661-671
Relationship between dietary fiber to carbohydrate ratio and mortality risk in US adults: NHANES 2007–2018
- 11 November 2023
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (3) , 661-671
Relationship between dietary fiber to carbohydrate ratio and mortality risk in US adults: NHANES 2007–2018
- 12 August 2022
- Published by Wiley in British Journal of Haematology
- Vol. 199 (2) , 260-269
Prominence of NUDT15 genetic variation associated with 6‐mercaptopurine tolerance in a genome‐wide association study of Japanese children with acute lymphoblastic leukaemia
Summary: Inherited genetic variation is associated with 6‐mercaptopurine (6‐MP) dose reduction and frequent toxicities induced by 6‐MP. However, the tolerable dose for 6‐MP is not fully predicted by the known variation in NUDT15 and TPMT among Asian children with acute lymphoblastic leukaemia (ALL). We performed a genome‐wide association study (GWAS) related to 6‐MP dose among Japanese children with ALL. This GWAS comprised 224 patients previously enrolled in Tokyo Children's Cancer Study Group clinical studies with replication attempted in 55 patients. Genome‐wide single nucleotide polymorphism (SNP) genotypes were evaluated for association with average 6‐MP dose during the initial 168 days of maintenance therapy. Possible associations were observed across five gene‐coding regions, among which only variants at 13q14.2 were significant and replicated genome‐wide (rs116855232, NUDT15, β = −10.99, p = 3.7 × 10−13). Notable findings were observed for variants in AFF3 (rs75364948, p = 2.05 × 10−6) and CHST11 (rs1148407, p = 2.09 × 10−6), but were not replicated possibly due to small numbers. A previously reported candidate SNP in MTHFR was associated with higher average 6‐MP dose (rs1801133, p = 0.045), and FOLH1 (rs12574928) was associated in an evaluation of candidate regions (padjust = 0.013). This study provides strong evidence that rs116855232 in NUDT15 is the genetic factor predominantly associated with 6‐MP tolerable dose in children in Japan.
- 12 August 2022
- Published by Wiley in British Journal of Haematology
- Vol. 199 (2) , 260-269
Prominence of NUDT15 genetic variation associated with 6‐mercaptopurine tolerance in a genome‐wide association study of Japanese children with acute lymphoblastic leukaemia
Summary: Inherited genetic variation is associated with 6‐mercaptopurine (6‐MP) dose reduction and frequent toxicities induced by 6‐MP. However, the tolerable dose for 6‐MP is not fully predicted by the known variation in NUDT15 and TPMT among Asian children with acute lymphoblastic leukaemia (ALL). We performed a genome‐wide association study (GWAS) related to 6‐MP dose among Japanese children with ALL. This GWAS comprised 224 patients previously enrolled in Tokyo Children's Cancer Study Group clinical studies with replication attempted in 55 patients. Genome‐wide single nucleotide polymorphism (SNP) genotypes were evaluated for association with average 6‐MP dose during the initial 168 days of maintenance therapy. Possible associations were observed across five gene‐coding regions, among which only variants at 13q14.2 were significant and replicated genome‐wide (rs116855232, NUDT15, β = −10.99, p = 3.7 × 10−13). Notable findings were observed for variants in AFF3 (rs75364948, p = 2.05 × 10−6) and CHST11 (rs1148407, p = 2.09 × 10−6), but were not replicated possibly due to small numbers. A previously reported candidate SNP in MTHFR was associated with higher average 6‐MP dose (rs1801133, p = 0.045), and FOLH1 (rs12574928) was associated in an evaluation of candidate regions (padjust = 0.013). This study provides strong evidence that rs116855232 in NUDT15 is the genetic factor predominantly associated with 6‐MP tolerable dose in children in Japan.
- 27 May 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (5) , 1397-1405
Association between fetal sex and pregnancy outcomes among women with twin pregnancies: a multicenter cross-sectional study
Purpose To examine the frequency and to what extent fetal sex is associated with pregnancy outcomes among twin pregnancies, stratified by chorionicity. Methods This registry-based multicenter cross-sectional study was conducted using the Japan Society of Obstetrics and Gynecology perinatal database between 2007 and 2016. The sample population was restricted to women with twin pregnancies. The main pregnancy-related outcomes included preterm birth, very preterm birth, extremely preterm birth, preeclampsia, twin-to-twin transfusion syndrome (TTTS), and selective intrauterine growth restriction (s-IUGR). Birth weight, small for gestational age (SGA), and fetal death were also investigated. Results The primary analysis was performed based on 37,953 women, including 23,804 women with dichorionic diamniotic (DD) twins and 14,149 women with monochorionic diamniotic (MD) twins. Women with male/male DD twins had a significantly higher risk of preterm birth (adjusted risk ratio [aRR]: 1.07, 95% confidence interval [CI]: 1.03–1.10) and a lower risk of preeclampsia (aRR: 0.74, 95% CI: 0.62–0.88) than women with female/female DD twins. Women with male/male MD twins also had a significantly higher risk of preterm birth (aRR: 1.06, 95% CI: 1.04–1.09) than women with female/female MD twins. Risks of preeclampsia, TTTS, and s-IUGR did not differ by sex among MD pregnancies. Male SGA risk was significantly higher among male/male twins than among male/female DD twins. Among MD twins, risks of SGA and fetal death were significantly higher in male/male fetuses. Conclusions This study demonstrated significant associations between fetal sex and several pregnancy outcomes in twin pregnancies, some of which differed by chorionicity.
- 27 May 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (5) , 1397-1405
Association between fetal sex and pregnancy outcomes among women with twin pregnancies: a multicenter cross-sectional study
Purpose To examine the frequency and to what extent fetal sex is associated with pregnancy outcomes among twin pregnancies, stratified by chorionicity. Methods This registry-based multicenter cross-sectional study was conducted using the Japan Society of Obstetrics and Gynecology perinatal database between 2007 and 2016. The sample population was restricted to women with twin pregnancies. The main pregnancy-related outcomes included preterm birth, very preterm birth, extremely preterm birth, preeclampsia, twin-to-twin transfusion syndrome (TTTS), and selective intrauterine growth restriction (s-IUGR). Birth weight, small for gestational age (SGA), and fetal death were also investigated. Results The primary analysis was performed based on 37,953 women, including 23,804 women with dichorionic diamniotic (DD) twins and 14,149 women with monochorionic diamniotic (MD) twins. Women with male/male DD twins had a significantly higher risk of preterm birth (adjusted risk ratio [aRR]: 1.07, 95% confidence interval [CI]: 1.03–1.10) and a lower risk of preeclampsia (aRR: 0.74, 95% CI: 0.62–0.88) than women with female/female DD twins. Women with male/male MD twins also had a significantly higher risk of preterm birth (aRR: 1.06, 95% CI: 1.04–1.09) than women with female/female MD twins. Risks of preeclampsia, TTTS, and s-IUGR did not differ by sex among MD pregnancies. Male SGA risk was significantly higher among male/male twins than among male/female DD twins. Among MD twins, risks of SGA and fetal death were significantly higher in male/male fetuses. Conclusions This study demonstrated significant associations between fetal sex and several pregnancy outcomes in twin pregnancies, some of which differed by chorionicity.
- Open Access
- 5 April 2022
- Published by Japan Epidemiological Association in Journal of Epidemiology
- Vol. 32 (4) , 168-173
Association Between Birth Weight and Risk of Pregnancy-Induced Hypertension and Gestational Diabetes in Japanese Women: JPHC-NEXT Study
Background: Although prevalence of low birth weight has increased in the last 3 decades in Japan, no studies in Japanese women have investigated whether birth weight is associated with the risk of pregnancy complications, such as pregnancy-induced hypertension (PIH) and gestational diabetes mellitus (GDM).Methods: We used data from the Japan Public Health Center-based Prospective Study for the Next Generation (JPHC-NEXT), a population-based cohort study in Japan that launched in 2011. In the main analysis, we included 46,365 women who had been pregnant at least once, for whom information on birth weight and events during their pregnancy was obtained using a self-administered questionnaire. Women were divided into five categories according to their birth weight, and the relationship between birth weight and risk of PIH and GDM was examined using multilevel logistic regression analyses with place of residence as a random effect.Results: Compared to women born with birth weight of 3,000–3,999 grams, the risk of PIH was significantly higher among women born <1,500 grams (adjusted odd ratio [aOR] 1.60; 95% confidence interval [CI], 1.17–2.21), 1,500–2,499 grams (aOR 1.16; 95% CI, 1.03–1.30), and 2,500–2,999 grams (aOR 1.13; 95% CI, 1.04–1.22). The risk of GDM was significantly higher among women born 1,500–2,499 grams (aOR 1.20; 95% CI, 1.02–1.42), albeit non-significant association among women in other birthweight categories.Conclusions: We observed an increased risk of PIH among women born with lower birth weight albeit non-significant increased risk of GDM among Japanese women.
- 5 April 2022
- Published by Japan Epidemiological Association in Journal of Epidemiology
- Vol. 32 (4) , 168-173
Open AccessAssociation Between Birth Weight and Risk of Pregnancy-Induced Hypertension and Gestational Diabetes in Japanese Women: JPHC-NEXT Study
Background: Although prevalence of low birth weight has increased in the last 3 decades in Japan, no studies in Japanese women have investigated whether birth weight is associated with the risk of pregnancy complications, such as pregnancy-induced hypertension (PIH) and gestational diabetes mellitus (GDM).Methods: We used data from the Japan Public Health Center-based Prospective Study for the Next Generation (JPHC-NEXT), a population-based cohort study in Japan that launched in 2011. In the main analysis, we included 46,365 women who had been pregnant at least once, for whom information on birth weight and events during their pregnancy was obtained using a self-administered questionnaire. Women were divided into five categories according to their birth weight, and the relationship between birth weight and risk of PIH and GDM was examined using multilevel logistic regression analyses with place of residence as a random effect.Results: Compared to women born with birth weight of 3,000–3,999 grams, the risk of PIH was significantly higher among women born <1,500 grams (adjusted odd ratio [aOR] 1.60; 95% confidence interval [CI], 1.17–2.21), 1,500–2,499 grams (aOR 1.16; 95% CI, 1.03–1.30), and 2,500–2,999 grams (aOR 1.13; 95% CI, 1.04–1.22). The risk of GDM was significantly higher among women born 1,500–2,499 grams (aOR 1.20; 95% CI, 1.02–1.42), albeit non-significant association among women in other birthweight categories.Conclusions: We observed an increased risk of PIH among women born with lower birth weight albeit non-significant increased risk of GDM among Japanese women.
- 5 January 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 60 (3) , 355-363
Bronchoscopy for the diagnosis of nontuberculous mycobacterial pulmonary disease: Specificity and diagnostic yield in a retrospective cohort study
- 5 January 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 60 (3) , 355-363
Bronchoscopy for the diagnosis of nontuberculous mycobacterial pulmonary disease: Specificity and diagnostic yield in a retrospective cohort study
- 14 November 2020
- Published by Wiley in Pediatrics International
- Vol. 63 (7) , 825-832
Trends in obesity and blood lipid abnormalities in school‐age children in Japan
Background: Obesity in children is a public health concern in Japan. To evaluate the current state of the obesity problem and inform future directions, we aimed to provide an updated account of secular trends in the percentage of overweight (POW) children by gender and school grade, and evaluate changes in POW after participation in the obesity health screening.Methods: The current study utilized aggregated data from the Setagaya Ward, Tokyo, public elementary and middle school populations from 2009 to 2018. Data on the percentage of overweight ≥ 30% (POW‐30) and percentage of abnormal blood test results were examined by year, gender, and school grade level. Individual‐level data from 2015 to 2017 in children who participated in a follow‐up obesity health screening were evaluated for changes in median POW.Results: A decreasing trend in students with a POW‐30 was observed from 2009 to 2011, with rates stabilizing thereafter. The highest proportions of POW‐30 were observed in 2010 (4.8% in middle school boys; 2.8% in middle school girls). From third grade, the difference in percentage by gender appeared to get increasingly larger until the beginning of middle school. Among obesity health screening participants, abnormal blood tests for total cholesterol and triglycerides showed a slightly increasing trend over time, and changes in POW after screening were greatest for middle school students.Conclusions: Increases in obesity were not observed in Setagaya Ward public school students since 2010, but disparities exist by gender and grade level, suggesting that tailored intervention strategies may be useful to optimize aspects of the obesity health screening program.
- 14 November 2020
- Published by Wiley in Pediatrics International
- Vol. 63 (7) , 825-832
Trends in obesity and blood lipid abnormalities in school‐age children in Japan
Background: Obesity in children is a public health concern in Japan. To evaluate the current state of the obesity problem and inform future directions, we aimed to provide an updated account of secular trends in the percentage of overweight (POW) children by gender and school grade, and evaluate changes in POW after participation in the obesity health screening.Methods: The current study utilized aggregated data from the Setagaya Ward, Tokyo, public elementary and middle school populations from 2009 to 2018. Data on the percentage of overweight ≥ 30% (POW‐30) and percentage of abnormal blood test results were examined by year, gender, and school grade level. Individual‐level data from 2015 to 2017 in children who participated in a follow‐up obesity health screening were evaluated for changes in median POW.Results: A decreasing trend in students with a POW‐30 was observed from 2009 to 2011, with rates stabilizing thereafter. The highest proportions of POW‐30 were observed in 2010 (4.8% in middle school boys; 2.8% in middle school girls). From third grade, the difference in percentage by gender appeared to get increasingly larger until the beginning of middle school. Among obesity health screening participants, abnormal blood tests for total cholesterol and triglycerides showed a slightly increasing trend over time, and changes in POW after screening were greatest for middle school students.Conclusions: Increases in obesity were not observed in Setagaya Ward public school students since 2010, but disparities exist by gender and grade level, suggesting that tailored intervention strategies may be useful to optimize aspects of the obesity health screening program.
- Open Access
- 5 October 2020
- Published by Japan Epidemiological Association in Journal of Epidemiology
- Vol. 30 (10) , 450-456
Municipality-Level Checklist to Promote Parental Behaviors Related to Prevention of Unintentional Injury in Young Children: A Multilevel Analysis of National Data
BackgroundUnintentional injury is a major cause of morbidity and mortality among young children in developed countries. In this national study, we examined the role of municipality-level safety checklist implementation for reducing risky child safety related parental behaviors.MethodsNationwide data were collected to evaluate the impact of the Healthy Parents and Children 21 initiative of the Japanese government. Questionnaires related to safety checklist implementation were administered to a random sample of municipal offices, and to parents at the child’s routine 1.5-year health exam on parental behaviors related to child safety. Adjusting for municipality and individual-level variables, multilevel analysis was used to examine the relationship between municipality checklist implementation (4-month health exam) and six child-safety–related parental behaviors at the 1.5-year health exam.ResultsFamilies (n=23,394) across 371 municipalities in Japan were included in this study; 5.6% of municipalities implemented a child safety intervention. Living in a municipality with a checklist intervention was associated with reduction in certain risk behaviors (not keeping tobacco/ashtray and candy out of the reach of infants, not using a car seat, not having a lock on bathing room door). However, after additionally taking into account municipality-level residual effects, only the “tobacco” behavior showed association with municipality of residence [Interval odds ratio (IOR)=0.25-0.94] and others were weak in the context of other potential municipality-level influences.ConclusionsA municipality-level intervention taking a checklist-based approach at the 4-month health exam in Japan appears to promote certain child safety behaviors in parents with children around 1.5 years of age.
- 5 October 2020
- Published by Japan Epidemiological Association in Journal of Epidemiology
- Vol. 30 (10) , 450-456
Open AccessMunicipality-Level Checklist to Promote Parental Behaviors Related to Prevention of Unintentional Injury in Young Children: A Multilevel Analysis of National Data
BackgroundUnintentional injury is a major cause of morbidity and mortality among young children in developed countries. In this national study, we examined the role of municipality-level safety checklist implementation for reducing risky child safety related parental behaviors.MethodsNationwide data were collected to evaluate the impact of the Healthy Parents and Children 21 initiative of the Japanese government. Questionnaires related to safety checklist implementation were administered to a random sample of municipal offices, and to parents at the child’s routine 1.5-year health exam on parental behaviors related to child safety. Adjusting for municipality and individual-level variables, multilevel analysis was used to examine the relationship between municipality checklist implementation (4-month health exam) and six child-safety–related parental behaviors at the 1.5-year health exam.ResultsFamilies (n=23,394) across 371 municipalities in Japan were included in this study; 5.6% of municipalities implemented a child safety intervention. Living in a municipality with a checklist intervention was associated with reduction in certain risk behaviors (not keeping tobacco/ashtray and candy out of the reach of infants, not using a car seat, not having a lock on bathing room door). However, after additionally taking into account municipality-level residual effects, only the “tobacco” behavior showed association with municipality of residence [Interval odds ratio (IOR)=0.25-0.94] and others were weak in the context of other potential municipality-level influences.ConclusionsA municipality-level intervention taking a checklist-based approach at the 4-month health exam in Japan appears to promote certain child safety behaviors in parents with children around 1.5 years of age.